{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:57:19Z","timestamp":1764079039404},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10549-014-3192-3","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T15:33:05Z","timestamp":1415979185000},"page":"511-523","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study"],"prefix":"10.1007","volume":"148","author":[{"given":"D.","family":"Balmativola","sequence":"first","affiliation":[]},{"given":"C.","family":"Marchi\u00f2","sequence":"additional","affiliation":[]},{"given":"M.","family":"Maule","sequence":"additional","affiliation":[]},{"given":"L.","family":"Chiusa","sequence":"additional","affiliation":[]},{"given":"L.","family":"Annaratone","sequence":"additional","affiliation":[]},{"given":"F.","family":"Maletta","sequence":"additional","affiliation":[]},{"given":"F.","family":"Montemurro","sequence":"additional","affiliation":[]},{"given":"J.","family":"Kulka","sequence":"additional","affiliation":[]},{"given":"P.","family":"Figueiredo","sequence":"additional","affiliation":[]},{"given":"Z.","family":"Varga","sequence":"additional","affiliation":[]},{"given":"I.","family":"Liepniece-Karele","sequence":"additional","affiliation":[]},{"given":"G.","family":"Cserni","sequence":"additional","affiliation":[]},{"given":"E.","family":"Arkoumani","sequence":"additional","affiliation":[]},{"given":"I.","family":"Amendoeira","sequence":"additional","affiliation":[]},{"given":"G.","family":"Callagy","sequence":"additional","affiliation":[]},{"given":"A.","family":"Reiner-Concin","sequence":"additional","affiliation":[]},{"given":"A.","family":"Cordoba","sequence":"additional","affiliation":[]},{"given":"S.","family":"Bianchi","sequence":"additional","affiliation":[]},{"given":"T.","family":"Decker","sequence":"additional","affiliation":[]},{"given":"D.","family":"Gl\u00e4ser","sequence":"additional","affiliation":[]},{"given":"C.","family":"Focke","sequence":"additional","affiliation":[]},{"given":"P.","family":"van Diest","sequence":"additional","affiliation":[]},{"given":"D.","family":"Grabau","sequence":"additional","affiliation":[]},{"given":"E.","family":"Lips","sequence":"additional","affiliation":[]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[]},{"given":"R.","family":"Arisio","sequence":"additional","affiliation":[]},{"given":"E.","family":"Medico","sequence":"additional","affiliation":[]},{"given":"C.","family":"Wells","sequence":"additional","affiliation":[]},{"given":"A.","family":"Sapino","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"issue":"9","key":"3192_CR1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206\u20132223","journal-title":"Ann Oncol"},{"issue":"1","key":"3192_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55\u201365","journal-title":"Lancet Oncol"},{"issue":"23","key":"3192_CR3","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726\u20133734","journal-title":"J Clin Oncol"},{"issue":"18","key":"3192_CR4","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2011.38.5740","volume":"30","author":"MJ Hassett","year":"2012","unstructured":"Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC (2012) Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30(18):2218\u20132226","journal-title":"J Clin Oncol"},{"issue":"8","key":"3192_CR5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160\u20131167","journal-title":"J Clin Oncol"},{"issue":"29","key":"3192_CR6","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1200\/JCO.2005.02.0818","volume":"23","author":"L Gianni","year":"2005","unstructured":"Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265\u20137277","journal-title":"J Clin Oncol"},{"issue":"3","key":"3192_CR7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-009-0333-1","volume":"119","author":"ME Straver","year":"2010","unstructured":"Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van\u2019t Veer LJ, Rodenhuis S (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119(3):551\u2013558","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"3192_CR8","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","volume":"24","author":"C Denkert","year":"2013","unstructured":"Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rudiger T, Erbstosser E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24(11):2786\u20132793","journal-title":"Ann Oncol"},{"key":"3192_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/1471-2407-11-486","volume":"11","author":"PA Fasching","year":"2011","unstructured":"Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486","journal-title":"BMC Cancer"},{"issue":"8","key":"3192_CR10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/j.1349-7006.2012.02319.x","volume":"103","author":"N Niikura","year":"2012","unstructured":"Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, Mori K, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y (2012) Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 103(8):1508\u20131512","journal-title":"Cancer Sci"},{"issue":"Suppl 10","key":"3192_CR11","doi-asserted-by":"crossref","first-page":"x219","DOI":"10.1093\/annonc\/mds307","volume":"23","author":"A Sheri","year":"2012","unstructured":"Sheri A, Dowsett M (2012) Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol 23(Suppl 10):x219\u2013x227","journal-title":"Ann Oncol"},{"issue":"5","key":"3192_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.surg.2014.01.009","volume":"155","author":"A Sueta","year":"2014","unstructured":"Sueta A, Yamamoto Y, Hayashi M, Yamamoto S, Inao T, Ibusuki M, Murakami K, Iwase H (2014) Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes? Surgery 155(5):927\u2013935","journal-title":"Surgery"},{"issue":"10","key":"3192_CR13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736\u2013750","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3192_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2013.11.007","volume":"23","author":"C Criscitiello","year":"2014","unstructured":"Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G (2014) High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. Breast 23(1):69\u201375","journal-title":"Breast"},{"issue":"12","key":"3192_CR15","doi-asserted-by":"crossref","first-page":"e81902","DOI":"10.1371\/journal.pone.0081902","volume":"8","author":"M Klintman","year":"2013","unstructured":"Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjallskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lovgren K, Skaland I, Bendahl PO, Malmstrom P, Baak JP, Ferno M (2013) The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One 8(12):e81902","journal-title":"PLoS One"},{"issue":"7","key":"3192_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2009.25.0407","volume":"29","author":"TH Lende","year":"2011","unstructured":"Lende TH, Janssen EA, Gudlaugsson E, Voorhorst F, Smaaland R, van Diest P, Soiland H, Baak JP (2011) In patients younger than age 55\u00a0years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol 29(7):852\u2013858","journal-title":"J Clin Oncol"},{"issue":"12","key":"3192_CR17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1634\/theoncologist.2008-0073","volume":"13","author":"F Penault-Llorca","year":"2008","unstructured":"Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X (2008) Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 13(12):1235\u20131245","journal-title":"Oncologist"},{"issue":"10","key":"3192_CR18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ejca.2004.03.014","volume":"40","author":"A Vincent-Salomon","year":"2004","unstructured":"Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, Rosty C, Nos C, Campana F, Klijanienko J, Al Ghuzlan A, Sastre-Garau X (2004) Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40(10):1502\u20131508","journal-title":"Eur J Cancer"},{"issue":"1","key":"3192_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1091\/mbc.E10-04-0335","volume":"23","author":"TJ Mitchison","year":"2012","unstructured":"Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23(1):1\u20136","journal-title":"Mol Biol Cell"},{"issue":"Suppl 2","key":"3192_CR20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.breast.2013.07.028","volume":"22","author":"G Minckwitz von","year":"2013","unstructured":"von Minckwitz G, Fontanella C (2013) Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit? Breast 22(Suppl 2):S149\u2013S151","journal-title":"Breast"},{"key":"3192_CR21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jncimonographs\/lgr025","volume":"43","author":"C Marchio","year":"2011","unstructured":"Marchio C, Sapino A (2011) The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr 43:86\u201390","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"8","key":"3192_CR22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.humpath.2007.11.019","volume":"39","author":"F Penault-Llorca","year":"2008","unstructured":"Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurteur M, Durando X, Achard JL, Gimbergues P, Chollet P (2008) Comparison of the prognostic significance of Chevallier and Sataloff\u2019s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 39(8):1221\u20131228","journal-title":"Hum Pathol"},{"issue":"5","key":"3192_CR23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403\u2013410","journal-title":"Histopathology"},{"issue":"4","key":"3192_CR24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2559.2006.02419.x","volume":"50","author":"SE Pinder","year":"2007","unstructured":"Pinder SE, Provenzano E, Earl H, Ellis IO (2007) Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50(4):409\u2013417. doi: 10.1111\/j.1365-2559.2006.02419.x","journal-title":"Histopathology"},{"issue":"2","key":"3192_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","volume":"31","author":"A Prat","year":"2013","unstructured":"Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31(2):203\u2013209. doi: 10.1200\/JCO.2012.43.4134","journal-title":"J Clin Oncol"},{"key":"3192_CR26","author":"R Salgado","year":"2014","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S (2014) Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol. doi: 10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"issue":"1","key":"3192_CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<61::AID-SIM297>3.0.CO;2-A","volume":"19","author":"D Faraggi","year":"2000","unstructured":"Faraggi D (2000) The effect of random measurement error on receiver operating characteristic (ROC) curves. Stat Med 19(1):61\u201370","journal-title":"Stat Med"},{"issue":"16","key":"3192_CR28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/1097-0258(20000830)19:16<2115::AID-SIM529>3.0.CO;2-M","volume":"19","author":"B Reiser","year":"2000","unstructured":"Reiser B (2000) Measuring the effectiveness of diagnostic markers in the presence of measurement error through the use of ROC curves. Stat Med 19(16):2115\u20132129","journal-title":"Stat Med"},{"issue":"2","key":"3192_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229\u2013235","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3192_CR30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/ejso.2002.1404","volume":"29","author":"VF Cocquyt","year":"2003","unstructured":"Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29(4):361\u2013367","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3192_CR31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41\u201348","journal-title":"J Clin Oncol"},{"issue":"2","key":"3192_CR32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/bjc.2012.557","volume":"108","author":"Y Delpech","year":"2013","unstructured":"Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L (2013) Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108(2):285\u2013291","journal-title":"Br J Cancer"},{"issue":"1","key":"3192_CR33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","volume":"144","author":"S Loibl","year":"2014","unstructured":"Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kummel S, Huober J, Denkert C, Hilfrich J, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M (2014) Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 144(1):153\u2013162","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3192_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-013-2751-3","volume":"142","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Barni S (2013) Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res Treat 142(2):227\u2013235","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3192_CR35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105\u2013113","journal-title":"J Clin Oncol"},{"issue":"7","key":"3192_CR36","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Investig 123(7):2873\u20132892","journal-title":"J Clin Investig"},{"issue":"10","key":"3192_CR37","doi-asserted-by":"crossref","first-page":"e26066","DOI":"10.4161\/onci.26066","volume":"2","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Willard-Gallo K (2013) Tumor-infiltrating follicular helper T cells: the new kids on the block. Oncoimmunology 2(10):e26066","journal-title":"Oncoimmunology"},{"issue":"7","key":"3192_CR38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860\u2013867","journal-title":"J Clin Oncol"},{"issue":"8","key":"3192_CR39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544\u20131550","journal-title":"Ann Oncol"},{"key":"3192_CR40","doi-asserted-by":"crossref","first-page":"S1000","DOI":"10.1200\/jco.2014.32.15_suppl.1000","volume":"32","author":"S Vinayak","year":"2014","unstructured":"Vinayak S, Gray RJ, Adams S, Jensen KC, Manola J, Afghahi A, Goldstein LJ, Ford JM, Badve SS, Telli ML (2014) Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. J Clin Oncol 32:S1000","journal-title":"J Clin Oncol"},{"key":"3192_CR41","doi-asserted-by":"crossref","unstructured":"Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A (2013) Adjuvant chemotherapy: which patient? What regimen? Am Soc Clin Oncol Educ Book 4:3-8","DOI":"10.1200\/EdBook_AM.2013.33.3"},{"issue":"22","key":"3192_CR42","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M, Nielsen TO, A\u2019Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103(22):1656\u20131664","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3192_CR43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10549-011-1837-z","volume":"132","author":"E Luporsi","year":"2012","unstructured":"Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895\u2013915","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"3192_CR44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/djt306","volume":"105","author":"MY Polley","year":"2013","unstructured":"Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897\u20131906","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3192_CR45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/modpathol.2012.140","volume":"26","author":"HA Lehr","year":"2013","unstructured":"Lehr HA, Rochat C, Schaper C, Nobile A, Shanouda S, Vijgen S, Gauthier A, Obermann E, Leuba S, Schmidt M, CCR, Delaloye JF, Simiantonaki N, Schaefer SC (2013) Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. Mod Pathol 26(3):336\u2013342","journal-title":"Mod Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3192-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-3192-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3192-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T10:36:30Z","timestamp":1566038190000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-3192-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,14]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-3192-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,14]]}}}